Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Throat Pastilles and Cough Drops Market 2026, Advantages Over Other Dosage Forms to Boost Growth - Technavio


NEW YORK, Sept. 27, 2022 /PRNewswire/ -- The throat pastilles and cough drop market is expected to grow by USD 1.11 billion during 2021-2026, at a CAGR of 3.61% during the forecast period, according to Technavio. The advantages over other dosage forms, increasing incidences of respiratory tract infections, and expanding geriatric population base will offer immense growth opportunities.

However, side effects and challenges associated with excipients, the fragmented nature of the market and the increasing use of homemade remedies will challenge the growth of the market participants.

To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Request Free Sample Report.

Throat Pastilles and Cough Drops Market Segmentation
Throat Pastilles and Cough Drops Market Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our throat pastilles and cough drops market report covers the following areas:

This study identifies the emergence of innovative products as one of the prime reasons driving the throat pastilles and cough drops market growth during the next few years. Buy Sample Report.

Throat Pastilles and Cough Drops Market Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the Throat Pastilles and Cough Drops Market, including some of the vendors such as vendors Backed with competitive intelligence and benchmarking, our research reports on the Throat Pastilles and Cough Drops Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Find additional highlights on the growth strategies adopted by vendors and their product offerings, Download Free Sample Report.

Throat Pastilles and Cough Drops Market Key Highlights
Related Reports:

Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography - Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by $ 1.47 bn from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 16.87%.

Lennox-Gastaut Syndrome Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The Lennox-Gastaut Syndrome (LGS) treatment market share is expected to increase by USD 684.75 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.42%.

Throat Pastilles And Cough Drops Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 3.61%

Market growth 2022-2026

$ 1.11 billion

Market structure

Fragmented

YoY growth (%)

3.21

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 34%

Key consumer countries

US, Canada, Mexico, Germany, UK, and Japan

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Blackmores Ltd., Dr. Willmar Schwabe India Pvt. Ltd., Ernest Jackson & Co. Ltd, GlaxoSmithKline Plc, iNova Pharmaceuticals, Island Abbey Foods Ltd., Johnson and Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Ricola Ltd., Sanofi SA, The Procter and Gamble Co., Belmora LLC, DISCH AG, Bliss GVS Pharma Ltd., Boyd Pharmaceuticals, Cipla Health Ltd., Lozys Pharmaceuticals SL, Thornton and Ross Ltd., and STADA Arzneimittel AG

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table Of Contents :

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio


These press releases may also interest you

at 00:47
TRADING STATEMENT FOR THE SIX MONTHS ENDING 31 DECEMBER 2022 Sasol shareholders are advised that for the six months ending 31 December 2022 (2023 financial half year) earnings per share (EPS) and headline earnings per share (HEPS) are expected to...

at 00:01
ATTOM, a leading curator of real estate data nationwide for land and property data, today released a Special Housing Risk Report spotlighting county-level housing markets around the United States that are more or less vulnerable to declines, based on...

at 00:00
As a psychologist in rural West Virginia during the pandemic, Don Worth, Ph.D. was surprised that many of his patients got better during the stay-at-home orders, and yet when restrictions were lifted, they drifted back to old routines and their...

30 nov 2022
IVERIC bio, Inc. (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition,...

30 nov 2022
Rubicon Organics Inc. ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis, is pleased to announce the publication of its second annual Environmental, Social and...

30 nov 2022
Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") , a publicly traded special purpose acquisition company ("SPAC") formed for the...



News published on 27 september 2022 at 06:15 and distributed by: